Jesse Jackson urges Biden to release AstraZeneca vaccine doeses for India

At a news conference in Chicago, American civil rights activist Rev Jesse Jackson said he would speak to Biden to immediately release 60 million doses of AstraZeneca vaccines to India

Topics
AstraZeneca | Coronavirus Vaccine

Press Trust of India  |  Washington 

Photo: Reuters
Photo: Reuters

A top American civil rights leader has urged President to release 60 million vaccine doses for India, which is battling a devastating second wave of the pandemic.

The vaccine has not been approved by the US and is unlikely to be used by the Biden administration.

Biden had recently said that he intended to give vaccines to other countries.

At a news conference in Chicago, American civil rights activist Rev Jesse Jackson said he would speak to Biden to immediately release 60 million doses of AstraZeneca vaccines to India.

Mass level vaccination is said to be the only cure to the current public health crisis in India, he said.

"They are human beings. As the wind blows, if we don't stop it today, it'll spread around the world, he said.

Expressing concern over the current situation in India, Rev Jackson said he will personally speak to the healthcare industry to donate oxygen concentrators and cylinders to India and follow up with the pharmaceutical giants to ensure therapeutic supplies to the country.

Other Indian Americans from the Chicago area echoed similar sentiments.

"It is everyone's duty to help India flatten this COVID-19 surge as we live in a world that cannot be separated by borders," said Dr Vijay Prabhakar, the chairman of American Association of Multiethnic Physicians.

"Based on the current projections some of the models are suggesting, there may be 1 million deaths by the end of August. As we know, that would be a tragic humanitarian crisis, said Dr Srinivas Reddy, the trustee of Chicago Medical Society.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Read our full coverage on AstraZeneca
First Published: Fri, May 07 2021. 06:16 IST
RECOMMENDED FOR YOU